-
GWAS expands list of Sjögren syndrome risk loci. Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-11 Sarah Onuora
-
SARS-CoV-2 vaccine safe for young patients. Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-11 Sarah Onuora
-
NETs implicated in COVID-19 in kids and adults. Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-11 Sarah Onuora
-
How does age determine the development of human immune-mediated arthritis? Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-10 Yannick Degboe, Sebastiaan J. Vastert, Berent J. Prakken, Iain B. McInnes
-
Risk variant regulates pDC hyperactivation in SLE Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-04 Jessica McHugh
New research attempts to explore the cause of plasmacytoid dendritic cell hyperactivation in systemic lupus erythematosus by focusing on genetic risk variation.
-
Sex- and gender-related differences in psoriatic arthritis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-04 Sanjana Tarannum, Ying-Ying Leung, Sindhu R. Johnson, Jessica Widdifield, Vibeke Strand, Paula Rochon, Lihi Eder
-
FABP4 exacerbates RA Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-03 Sarah Onuora
The findings of a new study suggest that the adipokine FABP4 promotes multiple pathological changes in rheumatoid arthritis and could represent a new therapeutic target.
-
Bimekizumab safe and effective for AS and PsA in long-term trials Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-03 Robert Phillips
Three new reports of results from two clinical trials of bimekizumab indicate that it is safe and efficacious for the long-term treatment of patients with ankylosing spondylitis or psoriatic arthritis.
-
Annexin A1 could help prevent periprosthetic bone loss Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-02 Sarah Onuora
New research shows that annexin A1 has a protective role in periprosthetic osteolysis and could offer a therapeutic approach to this common cause of arthroplasty failure.
-
A protective role for epidermal S100A9 in PsA Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-02 Jessica McHugh
A new study uncovers a protective role for epidermal S100A9 in psoriasis and psoriatic arthritis, and highlights this alarmin as a potential biomarker of disease progression.
-
FOXP3 splice variant is associated with autoimmune disease Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-01 Robert Phillips
New research shows that one of the two main isoforms of the human FOXP3 transcription factor is associated with inflammatory transcriptional regulation and autoimmunity.
-
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-25 Hyon K. Choi, Yuqing Zhang, Nicola Dalbeth
-
Discontinuing methotrexate to enhance vaccine response Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-22 Ana C. Medeiros-Ribeiro, Nadia E. Aikawa
In patients with autoimmune rheumatic disease, methotrexate therapy has been associated with poor immune response to vaccines, including those intended to provide protection against COVID-19. Emerging evidence supports the practice of temporarily discontinuing this treatment in order to improve immunogenicity.
-
Assessment of disease outcome measures in systemic sclerosis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-20 Robert Lafyatis, Eleanor Valenzi
-
Ikaros, Aiolos and other moving targets to treat SLE Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-13 Afroditi Boulougoura, George C. Tsokos
-
Cell–cell interactions shape RA and PsA pathogenesis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-11 Sarah Onuora
Transcriptomic analysis of synovial tissue from patients with rheumatoid arthritis and psoriatic arthritis reveals new details of the role of immune cell–stromal cell interactions in synovial inflammation.
-
Detachment promotes RA synovial fibroblast survival and invasiveness Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-11 Robert Phillips
New results have identified a targetable pathway involved in invasiveness and resistance to detachment-mediated apoptosis in rheumatoid arthritis synovial fibroblasts.
-
T cell differentiation in Sjögren syndrome is regulated by TOX Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-11 Robert Phillips
By isolating CD4+ T cells from patients with primary Sjögren syndrome, a new study has identified the involvement of a targetable interferon signalling pathway in T cell differentiation and B cell activation.
-
How the Russian invasion affects Ukrainian rheumatological health care Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-07-04 Bohdana Doskaliuk
Individuals with chronic diseases that require constant medical support are particularly vulnerable during wartime and often remain so after the last shot has been fired. What consequences might the Russia–Ukraine war bring for rheumatology?
-
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-27 Laura C. Coates, Enrique R. Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B. Campanholo, Jeffrey Chau, Lihi Eder, Daniel G. Fernández-Ávila, Oliver FitzGerald, Amit Garg, Dafna D. Gladman, Niti Goel, Philip S. Helliwell, M. Elaine Husni, Deepak R. Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo
-
Pregnancy outcomes in SLE have not improved. Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-01 Sarah Onuora
-
Low-dose glucocorticoids benefit seniors with RA. Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-08-01 Sarah Onuora
-
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-21 Lori Broderick, Hal M. Hoffman
-
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-15 Noriko Komatsu, Hiroshi Takayanagi
Rheumatoid arthritis (RA) is characterized by inflammation and destruction of bone and cartilage in affected joints. Autoimmune responses lead to increased osteoclastic bone resorption and impaired osteoblastic bone formation, the imbalance of which underlies bone loss in RA, which includes bone erosion, periarticular bone loss and systemic osteoporosis. The crucial role of osteoclasts in bone erosion
-
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-10 Sarah Onuora
Two new single-cell RNA sequencing studies provide insights into how disease-associated genetic variants influence gene expression in immune cells.
-
To choose or not? The value of discrete-choice experiments in rheumatology Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-09 Janet E. Pope
Do you inform patients about risks and chances of success associated with different choices when treatment needs to be changed? This approach takes time and requires patient health literacy. Results from a discrete-choice experiment in scleroderma lung disease add to the debate on shared decision-making.
-
Targeting UHRF1 in RA Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-07 Sarah Onuora
A new study suggests that drugs that stabilize the epigenetic regulator UHRF1 could offer a novel strategy for the treatment of rheumatoid arthritis.
-
Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-07 Mariola Kurowska-Stolarska, Stefano Alivernini
Synovial tissue macrophages (STMs) were principally recognized as having a pro-inflammatory role in rheumatoid arthritis (RA), serving as the main producers of pathogenic tumour necrosis factor (TNF). Recent advances in single-cell omics have facilitated the discovery of distinct STM populations, providing an atlas of discrete phenotypic clusters in the context of healthy and inflamed joints. Interrogation
-
Toward pre-treatment prediction of biologic DMARD response in RA Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-07 Robert Phillips
Results from the R4RA clinical trial indicate that gene signatures in pre-treatment biopsy-derived synovial tissue can predict the response to biologic DMARDs in patients with rheumatoid arthritis.
-
Novel TLR7 variant causes lupus Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-24 Michael Attwaters
New research has identified a novel, de novo mutation in the TLR7 gene that increases the affinity of TLR7 for guanosine, leading to TLR7 overactivation and child-onset systemic lupus erthematosus.
-
Skin inflammation precedes lesions in cutaneous lupus erythematosus Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-24 Robert Phillips
A detailed examination of skin cytology in cutaneous lupus erythematosus has identified cellular interactions and an inflammatory environment that exist prior to lesion formation.
-
From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-23 Hans Ulrich Scherer, Diane van der Woude, Rene E. M. Toes
The presence of disease-specific autoantibody responses and the efficacy of B cell-targeting therapies in rheumatoid arthritis (RA) indicate a pivotal role for B cells in disease pathogenesis. Important advances have shaped our understanding of the involvement of autoantibodies and autoreactive B cells in the disease process. In RA, autoantibodies target antigens with a variety of post-translational
-
Towards the patient-centred care of rheumatoid arthritis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-20 Zara Izadi, Gabriela Schmajuk
New research reveals that outcomes for patients with rheumatoid arthritis are affected less by pre-existing comorbid conditions than by socioeconomic factors. Future research should address the mechanisms of this relationship and develop holistic treatment approaches that reduce disparities attributed to socioeconomic status.
-
Improving the design of RCTs in non-radiographic axial spondyloarthritis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-13 Walter P. Maksymowych, Robert G. W. Lambert, Liron Caplan, Filip E. van den Bosch, Mikkel Østergaard
Concerns have been raised that randomized placebo-controlled trials (RCTs) in non-radiographic axial spondyloarthritis (nr-axSpA) might be failing to identify patients that best show differences in clinical response rates between those receiving active drug and those receiving placebo therapies; in addition, some studies might even be showing spurious differences in responses to TNF and IL-17 inhibitor
-
sCD13 role in arthritis mediated via bradykinin receptor Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-11 Sarah Onuora
Discovery of B1R as the receptor for soluble CD13 identifies a potential new target for the treatment of inflammatory arthritis.
-
SLE risk variant regulates IRF8 expression Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-10 Sarah Onuora
New research elucidates the functional effects of a genetic variant associated with autoimmune disease.
-
Mechanisms and clinical implications of intervertebral disc calcification Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-09 Uruj Zehra, Marianna Tryfonidou, James C. Iatridis, Svenja Illien-Jünger, Fackson Mwale, Dino Samartzis
Low back pain is a leading cause of disability worldwide. Intervertebral disc (IVD) degeneration is often associated with low back pain but is sometimes asymptomatic. IVD calcification is an often overlooked disc phenotype that might have considerable clinical impact. IVD calcification is not a rare finding in ageing or in degenerative and scoliotic spinal conditions, but is often ignored and under-reported
-
Disorders of ubiquitylation: unchained inflammation Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-06 David B. Beck, Achim Werner, Daniel L. Kastner, Ivona Aksentijevich
Ubiquitylation is an essential post-translational modification that regulates intracellular signalling networks by triggering proteasomal substrate degradation, changing the activity of substrates or mediating changes in proteins that interact with substrates. Hundreds of enzymes participate in reversible ubiquitylation of proteins, some acting globally and others targeting specific proteins. Ubiquitylation
-
2021 ACR guideline for JIA reflects changes in practice Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-05 Roberta Naddei, Angelo Ravelli
The new ACR guideline for the treatment of juvenile idiopathic arthritis provides an update on several important topics, including management of oligoarthritis, temporomandibular joint arthritis and systemic-onset arthritis. Overall, the new guideline reflects changes in practice, but also highlights a concerning lack of high-quality evidence.
-
Psoriatic arthritis from a mechanistic perspective Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-05 Georg Schett, Proton Rahman, Christopher Ritchlin, Iain B. McInnes, Dirk Elewaut, Jose U. Scher
Psoriatic arthritis (PsA) is part of a group of closely related clinical phenotypes (‘psoriatic disease’) that is defined by shared molecular pathogenesis resulting in excessive, prolonged inflammation in the various tissues affected, such as the skin, the entheses or the joints. Psoriatic disease comprises a set of specific drivers that promote an aberrant immune response and the consequent development
-
Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-04 Nathalie Burg, Jane E. Salmon, Timothy Hla
Sphingosine 1-phosphate (S1P), which acts via G protein-coupled S1P receptors (S1PRs), is a bioactive lipid essential for vascular integrity and lymphocyte trafficking. The S1P–S1PR signalling axis is a key component of the inflammatory response in autoimmune rheumatic diseases. Several drugs that target S1PRs have been approved for the treatment of multiple sclerosis and inflammatory bowel disease
-
Targeting senescence in OA Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-05-03 Michael Attwaters
New research demonstrates that a hydrogel-based miRNA delivery system might have therapeutic potential to treat osteoarthritis by targeting chondrocyte senescence.
-
HLA autoimmunity risk alleles influence T cell receptor sequences Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-19 Robert Phillips
New research demonstrates that the amino acid composition of the hypervariable CDR3 region of T cell receptors is influenced by the presence of HLA risk alleles for autoimmune disease.
-
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-19 Ursula Fearon, Megan M. Hanlon, Achilleas Floudas, Douglas J. Veale
Activation of endothelium and immune cells is fundamental to the initiation of autoimmune diseases such as rheumatoid arthritis (RA), and it results in trans-endothelial cell migration and synovial fibroblast proliferation, leading to joint destruction. In RA, the synovial microvasculature is highly dysregulated, resulting in inefficient oxygen perfusion to the synovium, which, along with the high
-
Endothelial function and endothelial progenitor cells in systemic lupus erythematosus Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-07 Anselm Mak, Jerry Kok Yen Chan
The observations that traditional cardiovascular disease (CVD) risk factors fail to fully account for the excessive cardiovascular mortality in patients with systemic lupus erythematosus (SLE) compared with the general population have prompted in-depth investigations of non-traditional, SLE-related risk factors that contribute to cardiovascular complications in patients with SLE. Of the various perturbations
-
ACR and EULAR bring AAV classification into the twenty-first century Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-07 Matthew J. Koster, Kenneth J. Warrington
New classification criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis endorsed by ACR and EULAR reflect important developments in the field since the 1990 criteria were published, including bringing ANCA testing to the fore.
-
Targeting necroptosis for the treatment of myositis. Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-06-01 Kanneboyina Nagaraju,Melissa Morales
-
Identifying OA subgroups based on biochemical data Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-06 Michael Attwaters
A machine learning approach has been used to identify three distinct osteoarthritis endotypes based on biochemical markers related to joint tissue processes.
-
PGE2 receptor antagonist has potential to treat osteoarthritis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-05 Robert Phillips
New research has identified the therapeutic potential of a small-molecule inhibitor of the prostaglandin E2 receptor EP4 against pathophysiology and pain in osteoarthritis.
-
C4A copy number is associated with autoimmune disease Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-05 Robert Phillips
Low copy number of the complement component gene C4A is associated with the presence of autoantibodies and occurrence of systemic autoimmune inflammatory disease.
-
NEMO splice variant causes distinct autoinflammatory syndrome Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-04-05 Sarah Onuora
New research has identified an autoinflammatory syndrome caused by mutations in NEMO-encoding IKBKG, leading to NF-κB activation and type I interferon production.
-
Cardio-rheumatology: it’s time to collaborate Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-24 Lihi Eder, Paula Harvey
New EULAR recommendations offer useful guidance for improving cardiovascular health in patients with rheumatic and musculoskeletal disease. However, an interdisciplinary model of care is crucial to the optimal management of cardiovascular risk in these patients.
-
Oral surveillance and JAK inhibitor safety: the theory of relativity Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-22 Kevin L. Winthrop, Stanley B. Cohen
The published results of the post-marketing ORAL Surveillance study, which compared the Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with rheumatoid arthritis who have cardiovascular risk factors, have led to changes in the recommendations for the use of JAK inhibitors. Although new safety signals have emerged for tofacitinib, namely malignancy and cardiovascular
-
Challenges in the management of older patients with inflammatory rheumatic diseases Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-21 Marloes van Onna, Annelies Boonen
The rise in the number of people aged 65 years and older living with inflammatory rheumatic diseases such as rheumatoid arthritis is causing considerable challenges for clinicians. As patients get older, they are at an increased risk of multiple chronic diseases, a situation termed multimorbidity. Multimorbidity inevitably drives polypharmacy, where by a patient requires treatment with multiple medications
-
PLG nanoparticles target inflammatory monocytes in SSc Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-15 Sarah Onuora
PLG nanoparticles that bind MARCO+ monocytes could offer a novel approach to treating fibrotic diseases, including systemic sclerosis.
-
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-15 Ariane L. Herrick, Shervin Assassi, Christopher P. Denton
Diffuse cutaneous systemic sclerosis (dcSSc) is associated with high mortality resulting from early internal-organ involvement. Clinicians therefore tend to focus on early diagnosis and treatment of potentially life-threatening cardiorespiratory and renal disease. However, the rapidly progressive painful, itchy skin tightening that characterizes dcSSc is the symptom that has the greatest effect on
-
Freeing PDL1 alleviates autoimmunity Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-14 Sarah Onuora
New research shows that PD1 can be potentiated by freeing up its ligand, PDL1, from binding to CD80, thereby improving symptoms of autoimmune disease in animal models.
-
TNF inhibition enhances depletion of synovial fibroblasts by ferroptosis Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-10 Robert Phillips
New research shows that induction of ferroptosis can deplete synovial fibroblasts that are activated in rheumatoid arthritis, and that co-treatment with a TNF inhibitor enhances this depletion.
-
Treatment of axial spondyloarthritis: an update Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-10 Abhijeet Danve, Atul Deodhar
Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the past two decades. With advances in the discernment of immunopathogenesis of this disease, new therapies have become available, which are associated with substantial improvement in symptoms, signs and quality of life. The four broad categories of approved treatment options are physical therapy and exercise (which
-
Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases Nat. Rev. Rheumatol. (IF 32.286) Pub Date : 2022-03-10 Boglárka Soós, Ágnes Szentpétery, Hennie G. Raterman, Willem F. Lems, Harjit P. Bhattoa, Zoltán Szekanecz
Generalized bone loss (osteoporosis) and fragility fractures can occur in rheumatic and musculoskeletal diseases including rheumatoid arthritis and spondyloarthritis (SpA; including ankylosing spondylitis and psoriatic arthritis). In addition, rheumatoid arthritis can involve localized, periarticular bone erosion and, in SpA, local (pathological) bone formation can occur. The RANK–RANKL–osteoprotegerin